Le Lézard
Classified in: Health, Business
Subjects: NPT, JVN, TRI

Green Park Collaborative and Allergy & Asthma Network Launch coreASTHMA to Develop Consensus on Critical Outcomes in Moderate to Severe Asthma Clinical Research


BALTIMORE, Oct. 15, 2019 /PRNewswire/ -- The Green Park Collaborative (GPC), a major initiative of the Center for Medical Technology Policy (CMTP), is partnering with Allergy & Asthma Network (AAN), to develop a core set of outcomes to be used in pivotal and late phase clinical trials of therapies for moderate to severe asthma. This initiative, coreASTHMA, will engage patients, clinicians, regulators, payers, health technology assessors, product developers, and other key stakeholders in a structured consensus process to develop the core outcome set.

Asthma is a disease of chronic airway inflammation, with symptoms such as coughing, wheezing and shortness of breath impacting patients' daily functioning and quality of life. Despite multiple treatment options for management of asthma, many patients with severe or poorly controlled asthma fail to improve with existing treatments. With recent innovations in immunotherapy, new biologic drugs give hope for long-term control of asthma, particularly in patients who have had limited success with traditional therapies. However, these new drugs come with high price tags and more questions.

"With more biologic therapies for asthma in the drug development pipeline, the timing is ideal to consider how best to evaluate these new treatments for better-informed patient choices and policy assessments," says Donna Messner, President and CEO of CMTP.

"At this critical juncture, we want to ensure the patient voice translates to asthma research and policy decisions," said Tonya Winders, CEO of AAN. "This project will help facilitate a more transparent and patient-centered definition of value in asthma care."

About the Green Park Collaborative (GPC)
GPC is a major initiative of CMTP, an independent 501(c)(3) non-profit organization dedicated to improving the quality, relevance, and efficiency of clinical research. GPC is a multi-stakeholder forum for developing condition- and technology-specific study design recommendations to guide the creation of evidence needed to inform both clinical and payment decisions.

About Allergy & Asthma Network 
AAN is the leading nonprofit patient education and advocacy organization for people with asthma, allergies, and related conditions. AAN's patient-centered network unites individuals, families, healthcare professionals, industry, and government decision makers to improve health and quality of life for Americans with asthma and allergies. We specialize in making accurate medical information relevant and understandable to all while promoting evidence-based standards of care.

 

SOURCE Green Park Collaborative


These press releases may also interest you

at 01:40
Versant Ventures today announced that portfolio company Vividion Therapeutics has been acquired by Bayer AG for $1.5 billion up front and up to $500 million in potential future milestone payments. This acquisition represents one of the largest...

at 01:15
Core One Labs Inc. , , (the "Company" or "Core One") is a research and development company focused on bringing psychedelic medicines to market through the development and production of API grade psychedelic compounds, the advancement of psychedelic...

at 01:05
Regulatory News: Vifor Pharma Group reported profitable revenue growth in H1 supported by a strong recovery in Ferinject® / Injectafer® with sales up 22.8% at CER as a result of improved patient access as COVID-19 restrictions eased in key markets....

at 01:05
Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced...

at 01:00
Diagnos (FRA: 4D4A) is opening clinics and forming distribution partnerships all over the world, including Canada, Spain, Saudi Arabia, Mexico, Europe, Costa Rica and the U.S....

at 01:00
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/NASDAQ: PHAR) presents its preliminary (unaudited) financial report for the first six months of 2021 ended June 30, 2021. The Company will hold an analyst conference call...



News published on 15 october 2019 at 10:13 and distributed by: